Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
News coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.
Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin